The Novo Nordisk Foundation pledged 1.8 billion Danish crowns ($265 million) toward an initiative to enhance vaccines for respiratory illnesses.
This commitment stems from the foundation's substantial profits derived from the success of Novo Nordisk A/S's (NYSE: NVO) weight-loss drug Wegovy, positioning it as a potential significant philanthropic and ESG investor.
This new initiative aims to innovate and enhance vaccines for severe respiratory diseases, including tuberculosis, influenza, and group A streptococcus.
These diseases collectively contribute to over 2.5 million fatalities annually, as stated by the foundation.
"The ...